Director Ronald Hunt of Rallybio Corp filed a Form 4 on November 2, 2026, reporting the exercise of three stock options and acquisition of common stock on October 29, 2026.

Key Highlights

  • Three option exercises: Ronald Hunt exercised options covering 3,562 shares at $2.38, 9,196 shares at $7.60, and 2,062 shares at $15.28, all on October 29, 2026.
  • Total shares acquired: Hunt acquired 14,820 shares of Rallybio Corp common stock in direct ownership following the three transactions.
  • Transaction code M: All three transactions were coded "M," indicating exercises of derivative securities.
  • Retainer-linked option: According to the filing, the option at $7.60 per share "was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500."
  • Zero remaining derivative positions: After the exercises, Hunt's beneficially owned derivative securities in all three option positions fell to zero.
  • Reporting person role: Hunt is identified as a Director of Rallybio Corp, listed on NASDAQ:RLYB.

Ronald Hunt's October 2026 Option Exercises at Rallybio

According to the Form 4 filed with the SEC on November 2, 2026, director Ronald Hunt exercised three separate stock options in Rallybio Corp (NASDAQ:RLYB) on October 29, 2026. The filing discloses that the three exercises involved options with exercise prices of $2.38, $7.60, and $15.28 per share, covering 3,562, 9,196, and 2,062 shares of common stock, respectively. Following the transactions, Hunt's direct beneficial ownership of common stock totaled 14,820 shares.

The filing provides context for the option grants. The option at $2.38 per share was granted under the company's 2021 Equity Incentive Plan and "vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders." The option at $15.28 per share was similarly granted under the 2021 Equity Incentive Plan and "vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders." The option at $7.60 per share vested "in 12 equal installments, each on the last day of each month of calendar year 2025" and was issued in lieu of retainer fees of $51,500.

The filing notes that the price of the derivative security for the $7.60 option was $5.60, while the other two option exercises carried a reported derivative security price of $0. All three positions show zero remaining derivative securities beneficially owned following the reported transactions. The form was signed by Jonathan Lieber as Attorney-in-Fact on November 2, 2026.

What Was Disclosed

Director Ronald Hunt disclosed the exercise of three stock options in Rallybio Corp on October 29, 2026, resulting in the direct acquisition of 14,820 total shares of common stock and the elimination of all three derivative security positions.